Dr. Oliver Froescheis Appointed Compugen Senior VP, Corporate and Business Development

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Oliver Froescheis, Ph.D., has been appointed Senior Vice President, Corporate and Business Development. In his role, Dr. Froescheis will oversee the Company’s business development strategy and execution, reporting to Anat Cohen-Dayag, Ph.D., Compugen’s President and CEO. Dr. Froescheis joins Compugen from Roche’s Partnering organization where he most recently served as Director of Business Development and Licensing R&D Out-licensing.

We are delighted to have an executive with Oliver’s proven track record in the pharmaceutical industry join Compugen’s management team,” said Dr. Cohen-Dayag. “Oliver’s breadth of healthcare experience and broad expertise in the development and licensing of pharmaceuticals across various therapeutic areas including immuno-oncology makes him a strong addition to our company as we work to expand our innovative immuno-oncology pipeline and pursue additional collaboration opportunities.”

“Compugen has made tremendous progress in recent years in advancing first-in-class immuno-oncology drug candidates to the clinic, and recently presenting initial promising clinical data for its lead program, COM701,” said Oliver Froescheis, Ph.D. “In addition, Compugen has an impressive track record of collaborations with three big pharma players having successfully leveraged its innovative immuno-oncology portfolio generated from its unique computational capabilities. This innovative portfolio and underlying computational capabilities provide opportunities for future business collaborations. I am excited to join Compugen’s management team to support this effort and be a part of Compugen’s future growth.”

Dr. Oliver Froescheis brings to Compugen over 20 years of experience in the pharmaceutical industry where he held positions in research, project management, marketing and business development. Dr. Froescheis joins Compugen from Roche, where he spent the last 12 years in the Partnering organization, initially serving as Global Due Diligence Director for in-licensing and M&A projects, then acting as Director of Business Development & Licensing, responsible for oncology/immuno-oncology partnering projects and most recently leading R&D out-licensing across therapeutic areas. Dr. Froescheis holds a Diploma in Chemistry and a Ph.D. in Analytical Chemistry, both from the University of Ulm, Germany.




Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.